Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8143240 | SUN PHARM | 17α, 21-dihydroxypregnene esters as antiandrogenic agents |
Jan, 2023
(28 days ago) | |
US9211295 | SUN PHARM | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2023
(5 months from now) | |
US8865690 | SUN PHARM | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2023
(5 months from now) | |
US9486458 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(5 years from now) | |
US10159682 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Aug, 2028
(5 years from now) | |
US11207332 | SUN PHARM | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Nov, 2028
(5 years from now) | |
US9433628 | SUN PHARM | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Feb, 2029
(6 years from now) | |
US8785427 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 26, 2025 |
NCE-1 date: August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate
Dosage: CREAM;TOPICAL
15
United States
8
European Union
5
Spain
5
Mexico
5
Portugal
5
Denmark
4
RS
4
Poland
4
Japan
4
Slovenia
4
Croatia
4
China
4
Canada
3
Hungary
3
Argentina
3
New Zealand
2
Korea, Republic of
2
Australia
2
Italy
2
South Africa
2
Russia
1
Austria
1
Brazil
1
Lithuania
1
Germany
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic